research Preclinical efficacy and safety evaluation of a topical mesenchymal stem cell derived conditioned media gel for oral mucositis management
The gel is safe and effective for treating oral mucositis from chemotherapy and radiation.
Search
for
Sort by
Research
60-90 / 1000+ results 
research SYSTEMATIC REVIEW OF PHARMACOTHERAPY STRATEGIES IN THE MANAGEMENT OF HIDRADENITIS SUPPURATIVA
Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.
research Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
research Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.
research Neuroendocrine Determinants of Polycystic Ovary Syndrome
Certain brain hormones and chemicals are linked to the development of Polycystic Ovary Syndrome.
research Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data
Incretin-based drugs for obesity often cause gastrointestinal issues, with tirzepatide having the most reports.
research Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
PCOS is influenced by various factors and may be managed by restoring gut health and using new therapies.
research Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiodiabetology, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Association of Polish Surgeons, and the College of Family Physicians in Poland
The conclusion is that obesity should be managed with a slow, balanced approach to diet and exercise, with medication and surgery as additional options, and education and access to care are important.
research The Role of MicroRNA, Long Non-Coding RNA and Circular RNA in the Pathogenesis of Polycystic Ovary Syndrome: A Literature Review
MicroRNAs could be key biomarkers and therapeutic targets for PCOS.
research Skin as a Metabolic Organ: Dermatologic Markers of Morbid Obesity and Their Role in Risk Stratification and Treatment Monitoring
Skin changes in obesity can indicate metabolic issues but aren't reliable for assessing risk or monitoring treatment.
research New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching
Tirzepatide users experience more hair loss than semaglutide users.
research The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
GLP-1 receptor agonists may help or harm hair health, needing more research.
research Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy
PCOS is a complex condition in women that can lead to health issues, and lifestyle changes are the best management approach.
research Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Treatments for PCOS aim to reduce androgen levels and improve insulin sensitivity to lower cardiometabolic risk.
research The Implication of Mechanistic Approaches and the Role of the Microbiome in Polycystic Ovary Syndrome (PCOS): A Review
Changes in gut bacteria can contribute to the development of Polycystic Ovary Syndrome (PCOS), affecting metabolism, immunity, and causing inflammation. Treatments may involve adjusting these factors.
research Mechanisms of Impaired Skeletal Muscle Regeneration and Therapeutic Approaches in Aging and Chronic Disease
Aging and chronic diseases impair muscle repair, but integrated therapies like exercise and gene editing may help.
research Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response
Lowering HER2 levels with certain drugs may reduce metabolic syndrome risk in women.
research Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
Methimazole for hyperthyroidism has known and new side effects needing more study for safety.
research Sex-Related Differences in the Pharmacological Response in SARS-CoV-2 Infection, Dyslipidemia, and Diabetes Mellitus: A Narrative Review
Men and women respond differently to drugs for COVID-19, high cholesterol, and diabetes, which suggests a need for personalized treatments.
research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
research Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
Drug repositioning is a promising way to quickly develop new treatments, especially for rare diseases.
research 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.
research 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization
GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.
research Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action
Methylene blue, combined with ceramides, may reduce skin and hair side effects from GLP-1 therapy.
research GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
GLP-1 receptor agonists may increase the risk of hair loss, especially non-scarring types, due to weight loss-related nutrient deficiencies.
research GLP-1 e Estética: Ozempic Face, Flacidez e Recuperação
GLP-1 medications can cause skin and muscle issues, but treatments like ultrasound and PRP can help.
research GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
research Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia
Hair shedding is common in GLP-1 users, affecting treatment adherence.
research GLP‐1 agonists and hair loss: a call for further investigation
More research is needed to understand if GLP-1 agonists affect hair health.